The Online Investor
Vericel Corp (ASTM)

Vericel is a clinical-stage biotechnology company focused on developing cell therapies that repair and regenerate damaged tissue for use in the treatment of severe, chronic ischemic cardiovascular diseases. Co.'s principal product, ixmyelocel-T is in a clinical development program for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy, critical limb ischemia and craniofacial reconstruction, as well as preclinical research and development programs for the treatment of cardiovascular diseases.
Company Name: 
Vericel Corp
Quotes delayed 20 minutes

Email EnvelopeFree ASTM Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Vericel Corp (ASTM) Page | The Online Investor Page |

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.